Kanawha Capital Management LLC held its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,672 shares of the medical equipment provider’s stock at the end of the second quarter. Kanawha Capital Management LLC’s holdings in Zimmer Biomet Holdings were worth $471,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in ZBH. Parkside Financial Bank & Trust boosted its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after buying an additional 199 shares in the last quarter. IHT Wealth Management LLC boosted its stake in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 256 shares in the last quarter. Sandy Spring Bank boosted its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares in the last quarter. Finally, Penserra Capital Management LLC boosted its stake in shares of Zimmer Biomet Holdings by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,288 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 112 shares in the last quarter. Institutional investors and hedge funds own 83.62% of the company’s stock.

Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 117.93 on Monday. The firm’s 50-day moving average is $127.65 and its 200 day moving average is $121.39. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49. The firm has a market cap of $23.80 billion, a PE ratio of 33.59 and a beta of 1.20.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same period last year, the business earned $2.02 EPS. The firm’s revenue was up 1.1% compared to the same quarter last year. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 28th. Shareholders of record on Friday, June 23rd were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.81%. The ex-dividend date was Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is 27.59%.

WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/07/zimmer-biomet-holdings-inc-nysezbh-position-maintained-by-kanawha-capital-management-llc.html.

A number of equities research analysts have weighed in on the stock. Cantor Fitzgerald set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the company a “hold” rating in a research report on Thursday, July 27th. BidaskClub cut shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Canaccord Genuity cut shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and dropped their price target for the company from $141.00 to $135.00 in a research report on Friday, July 28th. Oppenheimer Holdings, Inc. set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a research report on Friday, July 28th. Finally, BMO Capital Markets lifted their price target on shares of Zimmer Biomet Holdings from $136.00 to $140.00 and gave the company an “outperform” rating in a research report on Friday, July 28th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. Zimmer Biomet Holdings presently has a consensus rating of “Hold” and a consensus price target of $137.76.

In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sang Yi sold 17,731 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is owned by company insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.